Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain

Inclusion Criteria: * Diagnosis of diabetic neuropathy or complex regional pain syndrome of at least 6 months duration * VAS score of 4 cm or higher at Screening * No clinical abnormality in laboratory and urine analyses * Electrocardiogram within normal limits at Screening * Negative pregnancy test on Study Day 1 for female subjects of childbearing potential * On stable doses of medications, analgesic or others for at least 8 weeks prior to study enrollment * Willing to use barrier contraceptive during the period of the study Exclusion Criteria: * Known hypersensitivity to AV411 or its components * Conditions which might affect drug absorption, metabolism or excretion * Untreated mental illness, current drug addiction or abuse or alcoholism * Donated blood in the past 90 days or have poor peripheral venous access * Platelets \<100,000mm3 or a history of thrombocytopenia * Known or suspected chronic liver disease * GFR \<=90mL/min/1.73m2 (Cockcroft-Gault) * Female subjects who are pregnant or nursing mothers * Received an investigational drug in the past 90 days * Unable to swallow large capsules